Evidence map›Paper›PMID 40699935›Full record

ReviewFASEB journal : official publication of the Federation of American Societies for Experimental Biology2025

Engineering Nanoparticles and Bioscaffolds for Targeted microRNA Delivery in Cardiovascular Regeneration-A Comprehensive Review.

Jekhan Andimadam Madana Saravanan, Azam Ali, Rajesh Katare

Abstract readReview
In one paragraph

Review in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Decellularized cardiac ECM: A tissue-specific bioactive platform for drug release and cell delivery.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Review
  2. Cardioprotective Effects ofLife (Basel, Switzerland) · 2026
    Review
  3. Review
  4. Review
  5. Engineering Nanoparticles and Bioscaffolds for Targeted microRNA Delivery in Cardiovascular Regeneration-A Comprehensive Review.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jekhan Andimadam Madana SaravananDepartment of Physiology, HeartOtago, School of Biomedical Sciences, University of Otago, Dunedin North, New Zealand.
Azam AliCentre of Bioengineering and Nanomedicine, Faculty of Dentistry, University of Otago, Dunedin North, New Zealand.
Rajesh KatareDepartment of Physiology, HeartOtago, School of Biomedical Sciences, University of Otago, Dunedin North, New Zealand.ORCID https://orcid.org/0000-0001-5419-7935

Funding

Ministry of Business, Innovation and Employment (MBIE) UOOX220
6 · The paper itself

Abstract

Cardiovascular diseases, particularly myocardial infarction (MI), remain a leading cause of mortality worldwide, primarily due to the extensive loss of cardiomyocytes and the heart's limited regenerative capacity. MI, caused by obstructed blood flow, results in cardiac muscle damage, scar tissue formation, and ultimately, heart failure. While heart transplantation is the definitive treatment, its application is limited by donor shortages and the risk of immune rejection. This underscores the urgent need for regenerative strategies. MicroRNAs (miRNAs) play a crucial role in regulating myocardial healing post-ischemia, with specific miRNAs such as miR-92a, miR-126, and miR-145 shown to promote angiogenesis. However, the therapeutic application of miRNAs is hindered by delivery challenges at both extracellular and intracellular levels. This review explores the potential of nanoparticles (NPs) and engineered bioscaffolds to address these obstacles. We first examine the role of miRNAs in post-MI cardiovascular remodeling, followed by an overview of current challenges in miRNA-based therapy delivery. We then discuss the use of NPs and electrospun nanofibrous scaffolds in this context. Finally, we review existing cardiac bioscaffolds, their limitations, and future directions for developing optimized nanofibrous scaffolds for effective cardiac regeneration.

Indexed as

Cardiovascular DiseasesMicroRNAsNanoparticlesRegenerationTissue EngineeringTissue ScaffoldsAnimalsGene Transfer TechniquesHumansMyocardial InfarctionMicroRNAsbioscaffoldcardiac regenerationelectrospinningmicroRNAmyocardial infarctionnanoparticle

Identifiers

PMID40699935
PMCPMC12285754

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.